Volociximab
Based on 2 publication(s) in Google Scholar
Volociximab (M200) is a chimeric human/murine IgG4 antibody IIA1 targeting integrin α5β1 (EC50=0.2 nM). Integrin α5β1 is a major fibronectin receptor involved in angiogenesis. Volociximab has antiangiogenic and antitumor activities and inhibits the proliferation of human umbilical vein vascular endothelial cells (HUVECs).
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: ≥99.0%
- CAS No.: 558480-40-3
- Masse moléculaire:145.5 kDa
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
- Pureté et documentation
- Références
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Volociximab
More
Activité biologique
Human IgG4 kappa
Human
|
α5β1 0.2 nM (EC50) |
Volociximab (20, 40, 80, 160, 320 nM) specifically targets integrin α5β1 (Kd=0.367 nM), but not integrin α5α5 or β1β1[1].
Volociximab (0.01-100 nM; 4 d) inhibits the proliferation of human umbilical vein vascular endothelial cells (HUVEC) (IC50=0.2-0.5 nM) and (10 μg/mL; 16 h) induces apoptosis in schizogenic but not senescent Huvecs[1].
Volociximab (0.067-67 nM; 6 d) inhibits 0.1 μg/mL VEGF and/or bFGF induced HUVEC angiogenesis in vitro[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Volociximab (10 mg/kg; i.v.; twice weekly for 3 weeks) suppresses tumor progress in rabbits VX2 model[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Human IgG4 kappa
ELISA, FACS, Functional assay
-
Immobilized Integrin alpha 5 beta 1 Protein, Human (HEK293, Flag-His, HY-P73872) can bind Evinacumab. The EC50 for this effect is 13.19 ng/mL.
Chemical Information
-
CAS No. 558480-40-3
-
Appearance Liquid
-
Masse moléculaire 145.5 kDa
-
Color Colorless to light yellow
-
SMILES
[Volociximab]
-
Synonyms
M200; Eos 200-4
-
Livraison
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (2)
-
Journal Impact Factor
-
Most Recent
-
Cancer Commun (Lond)
Blocking ITGA5 potentiates the efficacy of anti-PD-1 therapy on glioblastoma by remodeling tumor-associated macrophages. [Abstract]2025 Jun;45(6):677-701. PMID: 40084746 -
Oncogene
Fibroblast Activation Protein (FAP)+ cancer-associated fibroblasts induce macrophage M2-like polarization via the Fibronectin 1-Integrin α5β1 axis in breast cancer. [Abstract]2025 Jul;44(28):2396-2412. PMID: 40263422
Pureté et documentation
-
Fiche technique (261 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
Références
[1]. Bhaskar V, et al. Volociximab, a chimeric integrin alpha5beta1 antibody, inhibits the growth of VX2 tumors in rabbits. Invest New Drugs. 2008 Feb;26(1):7-12. [Content Brief]
[2]. Ramakrishnan V, et al. Preclinical evaluation of an anti-alpha5beta1 integrin antibody as a novel anti-angiogenic agent. J Exp Ther Oncol. 2006;5(4):273-86. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Volociximab Related Classifications
HY-P99333 Related Classifications
Powered by Bioz